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転移陽性率は，（ ₁ ＋）₁₂．₅％，（ ₂ ＋）₅₀．₀％で，（ ₁ ＋）が有意に低かった．これらの結果は既報
告と同様の傾向で，（ ₁＋）ではALNDを省略できる可能性が示唆された．
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陽性とした．human epidermal growth factor receptor type ₂
（HER ₂ ）に関しては，免疫組織学的染色を行い，乳癌取
扱い規約に従って（ ₃ ＋）を陽性とした．（ ₂ ＋）は，原
則として fluorescence in situ hybridization（FISH）に提出

































OSNA（ ₂ ＋）が₁₂．₅%，（＋ I）が₁．₇%と，OSNA法で
微小転移の割合が大きく増加していた．なお，凍結切片
法による術中迅速診断ではSLN転移陰性であったが，術
















（ ₂ ＋）で₅₀．₀％がnon-SLN転移陽性であった． なお，
OSNA（＋ I）ではnon-SLN転移陽性例はなかった．OSNA
法でのSLN転移陽性例における，non-SLN転移陽性率の


































































































































































































T ₁ -T ₂ ，cN ₀ の乳房温存手術例において、SLN転移陽
性であってもALNDを省略できる可能性が示唆された． 














































ら₁₀）は，OSNA（ ₁ +）で₁₇．₆％，OSNA（ ₂ +）で₄₄．₀％，
久保田ら₉ ）はOSNA（ ₁ +）で₁₁．₁％，OSNA（ ₂ +）で
₃₃．₃％と報告している． 今回の自施設での検討でもOSNA






























（ ₁ +）ではnon-SLN転移陽性率が低いため，OSNA（ ₁ +）
でALNDが省略できる可能性が示唆された．
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Abstract
ONE-STEP NUCLEIC ACID AMPLIFICATION ASSAY FOR DIAGNOSIS OF  
SENTINEL LYMPH NODE METASTASES AND OMISSION OF  
AXILLARY LYMPH NODE DISSECTION
Akihiro Fujimoto ₁ ）, Ikuko ota ₁ ）, Masatoshi mogaki ₁ ）,  
Hidenobu masui ₁ ）, Satoru shimizu ₁ , ₂ ）, Kaoru Nagahori ₁ ）
₁ ）Department of Surgery, Yokosuka Kyosai Hospital 
₂ ）Department of Breast and Endocrine Surgery, Kanagawa Cancer Center
　A one-step nucleic acid amplification (OSNA) assay makes it possible to diagnose sentinel lymph node biopsy 
(SLNB) specimens when there is no pathologist available. However, there is little evidence for omission of axillary 
lymph node dissection (ALND) using an OSNA assay. The purpose of this study was to compare the results between 
conventional histopathologic examination and OSNA assay, and to evaluate the criteria for ALND when using an 
OSNA assay. Between ₂₀₁₂ and November ₂₀₁₆, ₃₆₉ breast cancer patients (pT₁-T₂ cN₀) who underwent SLNB 
were enrolled and assigned to OSNA assay (n=₁₇₆) or conventional histopathologic examination (n=₁₉₃). ALND 
was performed in all SLNB-positive cases. It was found that the OSNA assay detected SLN metastases at a higher 
rate than histopathologic examination, especially micrometastases. In the OSNA assay group of SLNB-positive 
cases, the rate of non-SLN metastases (₁₂.₅%) in the OSNA (₁+) group was significantly lower than the rate of non-
SLN metastases (₅₀.₀%) in the OSNA (₂+) group. This suggests that ALND can be omitted in OSNA (₁+) cases.
